Roffman Miller Associates’s CureVac CVAC Stock Holding History

Roffman Miller Associates’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50	Closed	-$521	–	102
2023 Q2	$521	Buy	+50	New	+$447	﹤0.01%	155

Other funds holding CVAC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Roffman Miller Associates's CVAC Position: Q3 2023 in Review

Roffman Miller Associates sold out of CureVac (CVAC) in Q3 2023, closing a stake of 50 shares — an estimated $521 sold.

Roffman Miller Associates first reported a position in CVAC in Q2 2023 and held it in 1 quarter. The position peaked at $521 in Q2 2023. 84 funds tracked by Wall St. Rank hold CVAC as of Q3 2023.

Roffman Miller Associates reported no remaining CureVac position as of Q3 2023 after selling out during the quarter.
Roffman Miller Associates sold 50 CureVac shares in Q3 2023, an estimated $521.
Roffman Miller Associates first reported a position in CureVac in Q2 2023 and held it in 1 quarter.
Roffman Miller Associates's CureVac position peaked at $521 in Q2 2023.
84 funds tracked by Wall St. Rank held CureVac as of Q3 2023.

Based on Roffman Miller Associates's 13F filing for Q3 2023, filed 9 Nov 2023.